The Therapeutic Value of Somatostatin and Its Analogues

被引：4

作者：

Farooqi S. ^{[1
]}

Bevan J.S. ^{[2
]}

Sheppard M.C. ^{[3
]}

Wass J.A.H. ^{[4
,5
]}

机构：

[1] Department of Medicine, Addenbrooke's Hospital, Cambridge

[2] Aberdeen Royal Infirmary, Aberdeen

[3] Queen Elizabeth Hospital, Birmingham

[4] Department of Endocrinology, Radcliffe Infirmary, Oxford

[5] Department of Endocrinology, Radcliffe Infirmary, Woodstock Road, Oxford

来源：

Pituitary | 1999年 / 2卷 / 1期

关键词：

D O I：

10.1023/A:1009978106476

中图分类号：

学科分类号：

摘要：

In this review we discuss the physiological effects of somatostatin, which are mediated by specific receptor subtypes on different tissues. These observations have suggested new therapeutic possibilities for the use of the synthetic somatostatin analogues in the treatment of acromegaly as well as a number of other endocrine and non-endocrine disorders.

引用

页码：79 / 88

页数：9

共 97 条

[21]

Bauer, W., Briner, U., Doepfner, W., SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action (1982) Life Sci, 31, pp. 1133-1140

[22]

Harris, A.G., Somatostatin and somatostatin analogues-pharmacokinetic and pharmacodynamic effects (1994) Gut, 35, pp. 1-4

[23]

Chanson, P., Timsit, J., Harris, A.G., Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours (1993) Clin Pharmacokinetics, 25, pp. 373-391

[24]

Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocrin Rev, 12, pp. 450-482

[25]

Lancranjan, I., Bruns, C., Grass, P., Sandostatin LAR: Pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients (1995) Metabolism, 44, pp. 18-26

[26]

Flogstad, A.K., Halse, J., Haldorsen, T., Lancranjan, I., Marbach, P., Bruns, C.H., Jervell, J., Sandostatin LAR in acromegalic patients: A dose-range study (1995) J Clin Endocrinol Metab, 80, pp. 3601-3607

[27]

Caron, P., Cogne, M., Gusthiot-Joudet, B., Wakim, S., Catus, F., Bayard, F., Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995) (1995) Eur J Endocrinol, 132, pp. 320-325

[28]

Hofland, L.J., Van Koetsveld, P.M., Waaijers, M., Zuyderwijk, J., Swj, L., Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells (1994) Endocrinology, 134, pp. 301-306

[29]

Bruns, C., Weckbecker, G., Raulf, F., Kaupmann, K., Schoeffter, P., Hoyer, D., Lubbert, H., Molecular pharmacology of somatostatin receptor subtypes (1994) Ann NY Acad Sci, 733, pp. 138-146

[30]

Kubota, A., Yamada, Y., Kagimoto, S., Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumours (1994) J Clin Invest, 93, pp. 1321-1325

← 1 2 3 4 5 6 7 8 9 10 →